Establishment Labs Holdings Inc Dossier
|
SectorHealth Care IndustryMedical Devices Beta (adjusted)1.06 Intrinsic Value $69.53median of 2 methodsbased on filings through 30 Jun 2026 Market Price $63.04Price as of 1 Oct 2026 Near fair valueIntrinsic value is 10% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $1.9B Enterprise Value $2.1B Shares Outstanding 30.8M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Establishment Labs Holdings Inc. (ESTA) is at a major commercial inflection point following the landmark U.S. FDA approval of its Motiva breast implants. The company's Q1 2026 results demonstrate powerful top-line acceleration, driven by a 216% year-over-year surge in U.S. sales and strong global adoption of its minimally invasive platform (Mia Femtech and Preservé). With gross margins expanding past 70% and a third consecutive quarter of positive adjusted EBITDA, the company is successfully demonstrating operating leverage. The recent $300 million refinancing with Oaktree Capital extends debt maturities to 2031, significantly reducing near-term balance sheet risk and providing the financial flexibility needed to fund its rapid U.S. expansion. While GAAP net losses persist, the path to free cash flow positivity in the second half of 2026 makes ESTA a highly attractive growth play in the medical aesthetics sector. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$92.00 Mean target$102.44 High · most bullish analyst$117.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The U.S. commercial launch faces stiffer-than-expected resistance from entrenched incumbents, or macroeconomic pressures on elective aesthetic procedures lead to a slowdown in overall market volumes. High commercialization and marketing expenses cause operating costs to exceed the $200 million threshold, delaying the transition to positive free cash flow. Persistent GAAP net losses and the high debt load under the Oaktree facility weigh on investor sentiment, leading to a contraction in the stock's premium valuation multiples. Base CaseCentral scenario The company successfully executes its U.S. commercial rollout, with Motiva implants capturing significant market share from legacy competitors. The minimally invasive platform exceeds its raised guidance of $35 million in 2026, representing at least 13% of total revenue. Favorable geographic and channel mix keeps gross margins within the guided 71.2% to 72.2% range. Operating expenses are well-controlled between $195 million and $200 million, allowing the company to achieve positive free cash flow in the second half of 2026 and sustain positive adjusted EBITDA every quarter. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |